Analystreport

Fulcrum Therapeutics, Inc. (NASDAQ: FULC) had its "overweight" rating re-affirmed by analysts at Piper Sandler.

Fulcrum Therapeutics, Inc.  (FULC) 
Last fulcrum therapeutics, inc. earnings: 3/5 07:00 am Check Earnings Report